Investors in Therapeutics

PPRS Venture positions itself uniquely in the biotech sector as "The Strategic Partnering Organization," specializing in innovative projects for diagnostics and therapeutics in neuroscience and orphan diseases. Based in Colmar, Alsace, with a subsidiary in Boston, USA, they combine independence in project selection with a multidisciplinary team of 25 associates. This team drives research collaborations encompassing over 100 stakeholders, from CROs to public and private labs. PPRS integrates robust financial and scientific expertise to support projects, from proof of concept to translational medicine, emphasizing risk management and global impact in their strategic approach.

We have taken over 70 companies to a successful exit since setting up the Novartis Venture Fund in 1996 – that is three on average per year. These exits have primarily resulted in IPOs and M&As, with several drugs receiving FDA approval. Nearly 40 companies completed initial public offerings (IPO) Over 30 progressed to a merger and acquisition by a number of top pharmaceutical companies.

Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. They balance the therapeutic focus with investments in medical devices, diagnostics, or drug delivery systems. In their investments, they look for unmet needs and clinical impact, novel proprietary science, an understanding of mechanism, management and board experience, and capital efficiency in the program. Novartis Venture Fund prefers to have their initial investment at the early stage to build the company and follow with additional investment in pace with the company's progress.

The BaseLaunch accelerator is tailored to the needs of healthcare startups. BaseLaunch is the Basel-based incubator and accelerator that helps scientists and entrepreneurs launch exceptional biotech companies. It serves as a growth platform for early-stage ventures developing cutting-edge therapeutics. Accelerating Therapeutic Ventures.

Seroba is a leading European life sciences venture capital firm, dedicated to creating value by supporting innovative biotech and medtech companies. With a focus on breakthrough technologies, Seroba has backed significant advancements such as Shorla Oncology's FDA-approved TEPYLUTE, a ready-to-dilute formulation for treating breast and ovarian cancer. Based in Dublin, Seroba leverages deep industry expertise to help entrepreneurs build world-class businesses, fostering extraordinary scientific innovations.

Droia is a specialist biotech investor with an exclusive focus on therapeutics for oncology and genetic disease. Droia invests globally in young drug development companies that use novel science and innovative approaches to bring promising therapies to patients. With our team of seasoned scientists, entrepreneurs and investment professionals we build great companies to save patients' lives.

NetScientific PLC (AIM: NSCI), we are a deep tech and life sciences venture capital investment group with a diverse international portfolio of innovative companies. Based in London, United Kingdom, our focus is on identifying, investing in, and nurturing high-growth businesses both locally and globally. Our approach involves adding significant value through proactive portfolio management, guiding companies towards key value inflection points, and achieving investment returns through strategic liquidity events. We distinguish ourselves by adopting a capital-light strategy, strategically managing our balance sheet, and syndicating investments through our wholly owned VC subsidiary, EMV Capital. This lean structure allows us to effectively support a broad portfolio while maintaining flexibility and scalability. Listed on AIM, a market operated by the London Stock Exchange, we uphold our commitment to transparency and accountability in all our investment operations.

BaseLaunch is the Basel-based incubator and accelerator that helps scientists and entrepreneurs launch exceptional biotech companies. It serves as a growth platform for early-stage ventures developing cutting-edge therapeutics. BaseLaunch helps build companies from inception through to Series A funding, providing financing and supporting all aspects of company creation and growth. It is operationally run and financed by Basel Area Business & Innovation, the investment and innovation promotion agency helping companies, institutions and startups find business success in the Basel area.

Praetura are a venture capital firm in the North West, who invest in early-stage businesses and provide 'more than money' support. We have developed a reputation for being a supportive and proactive investor who injects more than just capital. We can evidence the value from our differentiated approach from both investment returns and testament from our portfolio companies. Our partnered entrepreneurs embrace the shoulder to shoulder Praetura approach and utilise our experience and resource to maximise their businesses’ potential.

Delin Ventures is a mission-driven, early-stage investor and company builder specialising in cell therapy, the future of work, and the future of learning.

Columbus is a Spanish investment management company that focuses on generating high returns through the Columbus Innvierte Life Science fund. This fund targets seed-stage investments in established private companies within the healthcare and life sciences sectors. The company boasts a robust investment team with international experience and a proven track record in identifying innovative excellence originating from Spanish academic institutions. COLUMBUS VENTURE PARTNERS, SGEIC, SA leverages its expertise in company building and financing to accelerate commercialization for its portfolio companies. Additionally, it facilitates rapid access to the vibrant UK and Boston/Cambridge biotech/pharma venture capital R&D ecosystem.

Hummingbird Ventures is a global early stage venture capital fund backing outlier founders. They are global seed investors, looking for outlier founders. Hummingbird believes groundbreaking companies are built by a rare breed of entrepreneur.